SubsidieMeestersThe first effective and safe reversal agent to stop or prevent life-threatening bleeding in patients taking the emerging generation of anticoagulants.
VarmX aims to develop VMX-C001, the first safe reversal agent for FXa-DOACs, to reduce life-threatening bleeding risks in anticoagulant patients, seeking €2.5M grant and €15M equity for scaling production.
Projectdetails
Introduction
50 Million patients worldwide use oral anticoagulants to prevent venous thrombosis and stroke. Since the last decade, unpredictable and risky indirect anticoagulant treatments are being replaced by the latest generation of blood-thinning medication: Factor Xa Direct Oral Anticoagulants (FXa-DOACs, used by >10 million patients in EU+US).
Efficacy and Risks
With superior predictability, efficacy, and safety profiles, these life-saving medications remain associated with a risk of uncontrolled and severe bleeding. Alarmingly, there is no safe reversal agent that restores blood clotting in patients who take FXa-DOACs, resulting in life-threatening bleeding episodes and >400k hospital admissions.
Solution Development
To address the urgent unmet need, VarmX has developed VMX-C001, the first effective and safe reversal agent to FXa-DOACs.
Funding Request
VarmX requests a €2.5M grant and €15M in equity from EIC to accelerate upscaling and improve the cost-effectiveness of the complex manufacturing process required to produce VMX-C001.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 4.842.087 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 31-3-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- VARMX BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
EDV2209 – a Paradigm shift in the treatment of stroke.Edvince aims to revolutionize stroke treatment with its innovative drug EDV2209, enhancing cerebral blood flow to prevent brain damage from severe subarachnoid hemorrhage. | EIC Accelerator | € 2.500.000 | 2022 | Details |
APAC – the first targeted therapy for peripheral arterial occlusive disease.Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates. | EIC Accelerator | € 2.099.387 | 2022 | Details |
Revolutionary vascular repair patch to treat aortic dissectionsAortyx's biomimetic bioresorbable adhesive patch aims to treat aortic dissections via endovascular deployment, enhancing natural repair and reducing mortality compared to traditional stents. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThrThe RECOFIB platform produces customized, high-purity recombinant fibrinogen and thrombin from CHO cells, enabling innovative medical applications and reducing reliance on blood plasma. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Next-generation heart bypass grafts to naturally restore cardiovascular function.Xeltis aims to clinically validate a restorative vascular graft (XABG) to treat coronary artery disease without vein harvesting, enhancing patient outcomes and reducing healthcare costs. | EIC Accelerator | € 2.481.701 | 2022 | Details |
EDV2209 – a Paradigm shift in the treatment of stroke.
Edvince aims to revolutionize stroke treatment with its innovative drug EDV2209, enhancing cerebral blood flow to prevent brain damage from severe subarachnoid hemorrhage.
APAC – the first targeted therapy for peripheral arterial occlusive disease.
Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates.
Revolutionary vascular repair patch to treat aortic dissections
Aortyx's biomimetic bioresorbable adhesive patch aims to treat aortic dissections via endovascular deployment, enhancing natural repair and reducing mortality compared to traditional stents.
A unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThr
The RECOFIB platform produces customized, high-purity recombinant fibrinogen and thrombin from CHO cells, enabling innovative medical applications and reducing reliance on blood plasma.
Next-generation heart bypass grafts to naturally restore cardiovascular function.
Xeltis aims to clinically validate a restorative vascular graft (XABG) to treat coronary artery disease without vein harvesting, enhancing patient outcomes and reducing healthcare costs.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Recombinant fibrinogen for extravascular support (EVS) after vein bypass graftingFibriant BV ontwikkelt een kosteneffectieve, recombinant fibrinogeenvariant voor extravasculaire steun bij bypass chirurgie om afsluiting van getransplanteerde aderen te verminderen. | Mkb-innovati... | € 315.100 | 2015 | Details |
STOPtheBLEED – Ontwikkeling van unieke combinatie van stollingsfactoren en gelatine particles om ernstige bloedingen veroorzaakt door trauma te stoppenSTOPtheBLEED ontwikkelt een innovatief hemostaseproduct voor het snel en effectief stoppen van ernstige bloedingen door trauma, gericht op gebruik door niet-medische hulpverleners. | Mkb-innovati... | € 335.944 | 2016 | Details |
Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategiesRewind-MF aims to explore and develop innovative strategies for reversing bone marrow fibrosis in Primary Myelofibrosis, enhancing patient treatment options through advanced biological and computational methods. | ERC Consolid... | € 1.999.313 | 2024 | Details |
Targeting OGG1 in Idiopathic Pulmonary FibrosisThe TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch. | EIC Transition | € 2.499.998 | 2023 | Details |
Personalisation of Thrombosis Treatment (PoTT)Dit project ontwikkelt een betaalbaar meetapparaat voor gepersonaliseerde trombosebehandeling met Directe Orale Anti-Coagulantia. | 1.1 - Het ve... | € 569.565 | 2024 | Details |
Recombinant fibrinogen for extravascular support (EVS) after vein bypass grafting
Fibriant BV ontwikkelt een kosteneffectieve, recombinant fibrinogeenvariant voor extravasculaire steun bij bypass chirurgie om afsluiting van getransplanteerde aderen te verminderen.
STOPtheBLEED – Ontwikkeling van unieke combinatie van stollingsfactoren en gelatine particles om ernstige bloedingen veroorzaakt door trauma te stoppen
STOPtheBLEED ontwikkelt een innovatief hemostaseproduct voor het snel en effectief stoppen van ernstige bloedingen door trauma, gericht op gebruik door niet-medische hulpverleners.
Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies
Rewind-MF aims to explore and develop innovative strategies for reversing bone marrow fibrosis in Primary Myelofibrosis, enhancing patient treatment options through advanced biological and computational methods.
Targeting OGG1 in Idiopathic Pulmonary Fibrosis
The TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch.
Personalisation of Thrombosis Treatment (PoTT)
Dit project ontwikkelt een betaalbaar meetapparaat voor gepersonaliseerde trombosebehandeling met Directe Orale Anti-Coagulantia.